Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Single Arm, Open-label Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Vorasidenib in Pediatric Participants Aged 12 to < 18 Years Old With Grade 2 Astrocytoma or Oligodendroglioma With an IDH1 or IDH2 Mutation

NCT07286292 is registered in ClinicalTrials.gov with Institut de Recherches Internationales Servier (I.R.I.S.) as lead sponsor.

NCT NCT07286292
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07286292 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Single Arm, Open-label Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Vorasidenib in Pediatric Participants Aged 12 to < 18 Years Old With Grade 2 Astrocytoma or Oligodendroglioma With an IDH1 or IDH2 Mutation
Lead sponsor
Institut de Recherches Internationales Servier (I.R.I.S.)
Phase
Phase 2
Overall status
Recruiting
Start date
July 23, 2026
Completion date
May 2, 2033
Enrollment
10 (estimated)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

grade 2 astrocytoma or oligodendroglioma with an idh1 or idh2 mutation